|Other names||BMS-181100; MJ-14802|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||348.398 g·mol−1|
|3D model (JSmol)|
|NY (what is this?)|
BMY-14802, also known as BMS-181100, is a drug with antipsychotic effects which acts as both a sigma receptor antagonist and a 5-HT1A receptor agonist. It also has affinity for the 5-HT2 and D4 receptors. The drug reached phase III clinical trials for the treatment of psychosis but was never marketed.
See also: Receptor/signaling modulators